Bladder Cancer Clinical Trials in Dallas, Texas

14 studies are recruiting for bladder cancer in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer

    STAR-EV will evaluate the combination of enfortumab vedotin plus radiotherapy (RT) as neoadjuvant treatment for muscle invasive bladder cancer prior to radical cystectomy surgery. The study will use "dose escalation" to evaluate the safety and efficacy of study treatment at three dose regimens: Lev…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UT Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT06394570 on ClinicalTrials.gov

  2. DESTINY-PANTUMOUR04

    This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

    Stage
    Not phased
    Ages
    18 to 130
    Site
    Research Site, Dallas, Texas
    Locations
    18 in total
    Run by
    AstraZeneca

    See if you can join NCT07124000 on ClinicalTrials.gov

  3. Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

    This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizumab combination treatment. This trial will start with part A…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Research Site, Dallas, Texas
    Locations
    100 in total
    Run by
    Daiichi Sankyo

    See if you can join NCT07129993 on ClinicalTrials.gov

  4. Measuring Surgical Recovery After Radical Cystectomy

    The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating institutions. The goals of this initiative are to obtain a detailed baseline of multiple patient-reported outcomes (PRO) and cli…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Texas - Southwestern, Dallas, Texas
    Locations
    10 in total
    Run by
    M.D. Anderson Cancer Center

    See if you can join NCT03193970 on ClinicalTrials.gov

  5. Predicting BCG Response

    To date, there are no diagnostics capable of predicting treatment response to intravesical BCG. Because of this severe limitation, nearly 50% of patients treated with BCG fail therapy and will a) require additional intravesical therapy or b) require cystectomy. A urine-based diagnostic that possess…

    Stage
    Not phased
    Ages
    18 to 90
    Site
    University of Texas Southwestern, Dallas, Texas
    Locations
    6 in total
    Run by
    Cedars-Sinai Medical Center

    See if you can join NCT04564781 on ClinicalTrials.gov

  6. Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer

    This is a prospective, multicenter observational study designed to collect urine and tumor biospecimens and associated clinical data from patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.

    Stage
    Not phased
    Ages
    18 and older
    Site
    UT Southwestern Medical Center, Dallas, Texas
    Locations
    23 in total
    Run by
    Convergent Genomics, Inc.

    See if you can join NCT07673016 on ClinicalTrials.gov

  7. Bladder Cancer Screening Trial

    There is currently no accepted screening strategy for patients at high risk of developing bladder cancer. This study will ask patients to complete a urine test every 6 months for 2 years to help assess if routine screening helps finding bladder cancer at an earlier stage.

    Stage
    Not phased
    Ages
    50 and older
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT05646485 on ClinicalTrials.gov

  8. Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical prob…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    NEXT Oncology - Dallas, Dallas, Texas
    Locations
    13 in total
    Run by
    Tasca Therapeutics

    See if you can join NCT07030257 on ClinicalTrials.gov

  9. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mary Crowley Cancer Research, Dallas, Texas
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  10. A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer

    Voided urinary cytology (VUC) is the most widely used urine-based assay for detecting bladder cancer (BCa); however, it fails to detect approximately 50% of low-grade or early stage BCa when it is most curable. Furthermore, the detection rate of VUC for recurrent BCa is not much better. Because of …

    Stage
    Not phased
    Ages
    18 and older
    Site
    UT Southwestern Medical Center at Dallas, Dallas, Texas
    Locations
    4 in total
    Run by
    Cedars-Sinai Medical Center

    See if you can join NCT03193515 on ClinicalTrials.gov

  11. A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer

    To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.

    Stage
    Not phased
    Ages
    18 to 90
    Site
    UT Southwestern Medical Center at Dallas, Dallas, Texas
    Locations
    8 in total
    Run by
    Cedars-Sinai Medical Center

    See if you can join NCT03193541 on ClinicalTrials.gov

  12. A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

    A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Locations
    16 in total
    Run by
    OncoNano Medicine, Inc.

    See if you can join NCT06022029 on ClinicalTrials.gov

  13. Blue Light Cystoscopy With Cysview® Registry

    Registry study to gather more information on the current use of Blue Light Cystoscopy with Cysview (BLCC) in urologists' practices.

    Stage
    Not phased
    Ages
    18 and older
    Site
    UT Southwestern, Dallas, Texas
    Locations
    23 in total
    Run by
    Photocure

    See if you can join NCT02660645 on ClinicalTrials.gov

  14. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Dallas, Texas
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.